QGEN Stock Analysis: Qiagen | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 8.947m USD | 12M Return: 6.9% | NL0015002SN0 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 71.9M
EPS Trend: 82.7%
Qual. Beats: 1
Rev. Trend: 93.9%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Qiagen N.V. (NYSE: QGEN) is a Netherlands-based life sciences company that provides sample-to-insight solutions, converting biological materials into molecular insights for customers worldwide. Founded in 1984 and headquartered in Venlo, the Netherlands, Qiagen is classified within the Life Sciences Tools & Services sub-industry of the Health Care sector.
The companys business model centers on three integrated layers: consumables (kits, reagents, and enzymes used in sample preparation and analysis), instruments (PCR, digital PCR, NGS, and automated sample processing platforms), and bioinformatics/software solutions, including software-as-a-service offerings. This sample to insight approach is designed to give customers a workflow that spans from raw sample collection through data interpretation.
Qiagen serves two primary end markets. In molecular diagnostics, it offers tests for tuberculosis, post-transplant monitoring, sexually transmitted infections, HPV, and prenatal screening. In life sciences research, its products support gene expression analysis, genotyping, human ID/forensics, next-generation sequencing library preparation, and DNA methylation studies. The combination of recurring consumables revenue with instrument placements is a common structural feature of tools and services companies in this sector, supporting ongoing customer relationships beyond initial equipment sales.
- Core consumables sales accelerate as post-COVID demand recovers
- QIAstat-Dx respiratory panel placements drive instrument revenue growth
- Operating margin expansion initiative targets adjusted EBITDA margin lift
| Net Income: 409.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.92 > 1.0 |
| NWC/Revenue: 51.19% < 20% (prev 33.86%; Δ 17.33% < -1%) |
| CFO/TA 0.11 > 3% & CFO 654.5m > Net Income 409.3m |
| Net Debt (1.01b) to EBITDA (785.4m): 1.28 < 3 |
| Current Ratio: 2.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (207.8m) vs 12m ago -4.75% < -2% |
| Gross Margin: 61.82% > 18% (prev 62.97%; Δ -1.14% > 0.5%) |
| Asset Turnover: 35.86% > 50% (prev 35.03%; Δ 0.83% > 0%) |
| Interest Coverage Ratio: 12.68 > 6 (EBIT TTM 499.9m / Interest Expense TTM 39.4m) |
| A: 0.18 (Total Current Assets 1.66b - Total Current Liabilities 581.4m) / Total Assets 5.89b |
| B: 0.48 (Retained Earnings 2.81b / Total Assets 5.89b) |
| C: 0.09 (EBIT TTM 499.9m / Avg Total Assets 5.86b) |
| D: 1.33 (Book Value of Equity 3.36b / Total Liabilities 2.53b) |
| Altman-Z'' = 4.72 = AA |
| DSRI: 1.00 (Receivables 399.1m/385.8m, Revenue 2.10b/2.04b) |
| GMI: 1.02 (GM 62.97% / 61.82%) |
| AQI: 1.05 (AQ_t 0.56 / AQ_t-1 0.54) |
| SGI: 1.03 (Revenue 2.10b / 2.04b) |
| TATA: -0.04 (NI 409.3m - CFO 654.5m) / TA 5.89b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 44.18 with a total of 1,407,967 shares traded. Over the past week, the price has changed by +1.96%, over one month by +1.21%, over three months by +14.48% and over the past year by +6.92%.
Current recommended Stop Loss: 41.10 (which is 7% or 2.5 ATR below the current price).
Qiagen has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy QGEN.
- StrongBuy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 46.3 | 4.7% |
P/E Trailing = 21.9949
P/E Forward = 13.4228
P/S = 4.2599
P/B = 2.6647
P/EG = 1.1565
Revenue TTM = 2.10b USD
EBIT TTM = 499.9m USD
EBITDA TTM = 785.4m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 1.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 157.9m
Net Debt = 1.01b USD (calculated: Debt 1.80b - CCE 793.5m)
Enterprise Value = 9.96b USD (8.95b + Debt 1.80b - CCE 793.5m)
Interest Coverage Ratio = 12.68 (Ebit TTM 499.9m / Interest Expense TTM 39.4m)
EV/FCF = 22.24x (Enterprise Value 9.96b / FCF TTM 447.7m)
FCF Yield = 4.50% (FCF TTM 447.7m / Enterprise Value 9.96b)
FCF Margin = 21.32% (FCF TTM 447.7m / Revenue TTM 2.10b)
Net Margin = 19.49% (Net Income TTM 409.3m / Revenue TTM 2.10b)
Gross Margin = 61.82% ((Revenue TTM 2.10b - Cost of Revenue TTM 801.8m) / Revenue TTM)
Gross Margin QoQ = 63.62% (prev 62.89%)
Tobins Q-Ratio = 1.69 (Enterprise Value 9.96b / Total Assets 5.89b)
Interest Expense / Debt = 2.19% (Interest Expense 39.4m / Debt 1.80b)
Taxrate = 11.37% (52.5m / 461.8m)
NOPAT = 443.1m (EBIT 499.9m * (1 - 11.37%))
Current Ratio = 2.85 (Total Current Assets 1.66b / Total Current Liabilities 581.4m)
Debt / Equity = 0.54 (Debt 1.80b / totalStockholderEquity, last quarter 3.36b)
Debt / EBITDA = 1.28 (Net Debt 1.01b / EBITDA 785.4m)
Debt / FCF = 2.25 (Net Debt 1.01b / FCF TTM 447.7m)
Total Stockholder Equity = 3.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 409.3m / Total Assets 5.89b)
RoE = 11.60% (Net Income TTM 409.3m / Total Stockholder Equity 3.53b)
RoCE = 9.70% (EBIT 499.9m / Capital Employed (Equity 3.53b + L.T.Debt 1.63b))
RoIC = 8.49% (NOPAT 443.1m / Invested Capital 5.22b)
WACC = 6.25% (E(8.95b)/V(10.7b) * Re(7.12%) + D(1.80b)/V(10.7b) * Rd(2.19%) * (1-Tc(0.11)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.47 | Cagr: -3.77%
[DCF] Terminal Value 73.99% ; FCFF base≈467.1m ; Y1≈430.5m ; Y5≈384.0m
[DCF] Fair Price = 24.61 (EV 6.09b - Net Debt 1.01b = Equity 5.08b / Shares 206.5m; r=8.35% [WACC [floored]]; 5y FCF grow -9.80% → 2.50% )
EPS Correlation: 82.71 | EPS CAGR: 3.59% | SUE: 1.00 | # QB: 1
Revenue Correlation: 93.93 | Revenue CAGR: 3.36% | SUE: 1.15 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.62 | Chg30d=+0.45% | Revisions=-62% | Analysts=9
EPS current Year (2026-12-31): EPS=2.43 | Chg30d=+0.01% | Revisions=+22% | GrowthEPS=+2.3% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=2.61 | Chg30d=+0.11% | Revisions=-15% | GrowthEPS=+7.3% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -21% (up=8, down=13)